New Skin Cancer-Fighting Drug Keytruda Boosts Mesothelioma Survival

Help could be on the way for future mesothelioma patients who need it the most. Researchers in Spain are the first to successfully identify a specific protein found only in mesothelioma patients with the shortest survival times. The findings should provide a clearer target for potential therapy advances, giving those cancer patients more of a fighting chance. The Federal Drug Administration (FDA) earlier this year granted accelerated approval for the drug pembrolizumab, known by its brand name Keytruda, which is designed to target skin cancers. However, the drug also targets proteins in other cancers. Results Are Promising "The results of our study could offer new treatment options to this population of [mesothelioma] patients," wrote study author, Dr. Susana Cedrés, of the Vall d'Hebron Institute of Oncology in Barcelona, Spain. Cedrés presented the findings at the European Society of Medical Oncology Conference in September. Researchers found the protein called PD-L1 in the tissue samples of 20 percent of the malignant mesothelioma patients in their recent study. Those with the highest levels of PD-L1 had the shortest survival of the 119 patients studied between 2002 and 2014. Patients with the highest levels of PD-L1 had a median survival of just 4.79 months. The patients who tested negative for PD-L1 had a median survival of 16.3 months. Keytruda Successful on Other Cancers PD-L1, which works alongside another protein called PD-1, has been the ta...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Tags: Research & Clinical Trials Source Type: news

Related Links:

Cardiac tumors have generally been considered to be rare. They are often found incidentally as they tend to remain clinically silent, but they can sometimes present with symptoms secondary to obstruction, embolization, or invasion of the myocardium. Most cardiac tumors are secondary tumors from metastases, with primary cardiac tumors constituting approximately 15% of all cardiac tumors1. Although melanoma and pleural mesothelioma often have cardiac involvement, the most common cancers to be identified in cardiac metastases are lung cancer (36-39%), breast cancer (10-12%), and hematologic cancers (10-21%)2.
Source: The American Journal of Medicine - Category: General Medicine Authors: Tags: Clinical Communication to the Editor Source Type: research
Not every mesothelioma patient benefits from the immunotherapy drug Opdivo, but for the ones that do, the response can be lifesaving. Opdivo, known generically as nivolumab, continues to produce dramatic results, inching it closer to FDA approval for mesothelioma cancer. A recently published individual case report describes “an exceptional and sustained response.” Treatment with Opdivo allowed one patient to go from a downward spiral, with only weeks to live, back into the workforce. “We were blown away by the patient’s response,” lead author Riley Jones, now in his fellowship at the Universit...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
For mesothelioma patients, immunotherapy is mostly available through clinical trials at this time. Immunotherapy is a relatively new way to treat cancer, and doctors still are learning who will respond best to these novel therapies. Newly released medical research has found men seem to respond better to immunotherapy than women. But this doesn’t mean immunotherapy is off the table for women with mesothelioma. You should learn all you can about how immunotherapy works, why it may or may not be right for you and how you can best prepare yourself if you decide an immunotherapy clinical trial is right for you. Thorough ...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
Dr. Chukwuemeka Ikpeazu at the Sylvester Comprehensive Cancer Center has brought hope — where once there was none — to patients in South Florida with unresectable pleural mesothelioma. Ikpeazu is the principal investigator in the multicenter phase II clinical trial involving the much-anticipated immunotherapy drug durvalumab. Pharmaceutical giant AstraZeneca manufactures the drug under the brand name Imfinzi. “I am optimistic, very, very optimistic that this drug will be effective for these patients,” Ikpeazu told “All the data, all the earlier studies, are encouraging.” He...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
Conclusion: PTX3 could be a promising biomarker to differentiate PPE from other causes of pleural effusions. In PPE, an increased level of pleural fluid PTX3 level without a significant increase in serum PTX3 level may reflect a more intense local inflammation than those occur in MPE or TPE.
Source: European Respiratory Journal - Category: Respiratory Medicine Authors: Tags: Clinical Problems Others Source Type: research
In this study, we investigated podoplanin expression in 40 feline squamous cell carcinomas (14 cases of mouth floor, 13 of skin, 9 of ear, and 4 of tongue) by immunohistochemical analysis using an anti-cat podoplanin mAb PMab-52, which we recently developed by cell-based immunization and screening (CBIS) method. Of the total 40 cases, 38 (95%) showed positive staining for PMab-52. In particular, 12 cases (30%) showed a strong membrane-staining pattern of squamous cell carcinoma cells. PMab-52 can be useful for antibody therapy against feline podoplanin-expressing squamous cell carcinomas. PMID: 29090969 [PubMed - as supplied by publisher]
Source: Monoclonal Antibodies in Immunodiagnosis and Immunotherapy - Category: Microbiology Tags: Monoclon Antib Immunodiagn Immunother Source Type: research
Authors: Kim YR, Song MH, Lee JW, Bae JH, Kim JE, Kang DM, Lee SY Abstract Serological analysis of recombinant tumor cDNA expression library (SEREX) is a powerful and widely used method to explore the cancer immune environment. In the present study, immunoscreening of normal testicular tissues and malignant mesothelioma (MM) cancer MSTO-211H cell line cDNA libraries with sera from 5 MM patients led to the isolation of 16 independent antigens, which were designated 'Korea Pusan-Malignant Mesothelioma' (KP-MM)-1 to -16. In total, 3/16 antigens were identified using the results of previous SEREX analyses, and 13 were ...
Source: Oncology Letters - Category: Cancer & Oncology Tags: Oncol Lett Source Type: research
Malignant mesothelioma is a cancer caused by exposure to asbestos. It has a devastating prognosis, and its incidence has increased substantially in high-income countries during the past three decades. Systemic therapy comprising cisplatin and pemetrexed remains the only approved standard of care, a therapeutic plateau that has endured for more than 10 years. New, effective therapies based on an understanding of the underlying biology are clearly needed. By contrast with many other cancers, including lung cancer and melanoma, somatic mutations in oncogenic kinases have not been identified in the genomic landscape of mesotheliomas.
Source: The Lancet Oncology - Category: Cancer & Oncology Authors: Tags: Comment Source Type: research
Immunotherapy through clinical trials is becoming a promising treatment option for some mesothelioma patients. Checkpoint inhibitor drugs, such as Keytruda, already have U.S. Food and Drug Administration (FDA) approval as first-line treatments for non-small cell lung cancer (NSCLC), edging immunotherapy drugs closer to becoming a viable second-line therapy for other thoracic cancers, including pleural mesothelioma. However, overall response to immune therapies remains relatively low. Researchers across the country are striving to enhance responsiveness to immunotherapy drugs. Leading that trend is viroimmunotherapy, or t...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Tags: Biomedicines checkpoint blockade Checkpoint inhibitor drugs clinical trials for mesothelioma Dr. Alexander Dash Dr. Manish Patel FDA approval Keytruda immune response cancer immunotherapy response mesothelioma intratumoral injections k Source Type: news
Authors: Cappuccini F, Pollock E, Stribbling S, Hill AVS, Redchenko I Abstract The tumour-associated antigen 5T4 is an attractive target for cancer immunotherapy. However to date, reported 5T4-specific cellular immune responses induced by various immunisation platforms have been largely weak or non-existent. In the present study, we have evaluated a heterologous prime boost regime based on the simian adenovirus ChAdOx1 and modified vaccinia virus Ankara (MVA) expressing 5T4 for immunogenicity and tumour protective efficacy in a mouse cancer model. Vaccination-induced immune responses were strong, durable and attrib...
Source: Oncotarget - Category: Cancer & Oncology Tags: Oncotarget Source Type: research
More News: Asbestosis | Cancer | Cancer & Oncology | Cancer Therapy | Chemotherapy | Clinical Trials | Conferences | Environmental Health | Lung Cancer | Melanoma | Mesothelioma | Skin | Skin Cancer | Smokers | Study | Toxicology